What Броадсеф-С Treats: Main Uses and Benefits

This combination medicine is applied in clinical settings to treat serious and complex bacterial infections that cause severe symptoms. The active component is used to manage a wide range of serious infections in adults and children.

The therapeutic relevance is considered relevant for conditions such as pneumonia, deep-seated intra-abdominal infections, complicated infections of the urinary tract, infections of the bones and joints, and critical infections of the bloodstream (septicaemia) or Central Nervous System (meningitis).

Quick Fact: Supportive Relief for Systemic Stress

Context	Benefit
Symptom Type	Symptoms related to systemic imbalance and heightened physiological stress
Clinical Scenario	Used in hospital settings for acute, complicated episodes
Patient Benefit	Provides supportive relief that helps ease the overall symptom burden

The medication is applied in addressing clinical situations marked by significant high fever and profound malaise. It is relevant when symptoms create noticeable physiological strain and lead to functional distress, helping to manage the intense inflammatory response. This is considered relevant for use in clinical contexts where drug-resistant bacteria are suspected, offering a supportive therapeutic option for patient groups such as the immunocompromised or elderly.

Regulatory References

1. Summary of Product Characteristics - HPRA

Who can and cannot use Броадсеф-С? (Cefepime/Sulbactam)

Official regulatory information strictly defines eligibility and non-eligibility for this medicine. The drug is absolutely contraindicated for patients with a history of immediate hypersensitivity reactions to Cefepime, Sulbactam, other cephalosporins, penicillins, or any other beta-lactam antibacterial drugs.

---

Populations Requiring Restriction or Caution

Population/Condition	Eligibility Status	Regulatory Constraint
Renal Impairment	Restricted Use	Dosage must be adjusted based on Creatinine Clearance ( CrCL le 60 mL/ min) to prevent drug accumulation and neurotoxicity.
Infants (<2 months)	Use Not Established	Safety and efficacy have not been established in this age group.
Geriatric Patients	Caution Required	Requires careful dose selection and monitoring of renal function.
Pregnancy/Lactation	Caution Required	Use in pregnancy is only if clearly needed; drug is excreted in breast milk.
Neurological History	Caution Required	Patients with a history of seizures or encephalopathy require close monitoring due to the risk of neurotoxicity.

This eligibility profile ensures that the medicine is only administered to populations where the official safety and efficacy parameters are met or where constraints, such as mandatory dose adjustments for kidney function, are properly followed.

Interactions with other medicines and products

Critical Intravenous (IV) Incompatibility

The most significant interaction related to Броадсеф-С (which contains ceftriaxone) is the critical incompatibility with calcium-containing intravenous solutions and products. The active component (ceftriaxone) can form a potentially life-threatening precipitate with calcium when administered simultaneously via an IV line. This physical-chemical reaction makes concurrent administration of calcium-containing IV solutions (such as Ringer's solution, Hartmann's solution, or calcium gluconate) a contraindication, especially in neonates.

Other Documented Interactions

Ceftriaxone may also interact with other classes of medicines:

Interacting Product Category	Potential Effect	Severity Classification
Oral Anticoagulants (e.g., Warfarin)	Increased effect of the anticoagulant, raising the risk of bleeding.	Moderate/Major
Aminoglycoside Antibiotics (e.g., Gentamicin, Amikacin)	Increased risk of kidney-related side effects.	Moderate
Hormonal Contraceptives	May decrease the effectiveness of oral contraceptives.	Moderate
Probenecid	Can increase the concentration of ceftriaxone in the blood.	Moderate

It is essential to inform a healthcare professional about all prescription and non-prescription drugs, including vitamins and herbal supplements, before administration of Броадсеф-С to manage and monitor potential interactions effectively.

Direct Inhibition of Bacterial Cell Wall Synthesis

The primary antibiotic, Ceftriaxone, acts by irreversibly binding to Penicillin-Binding Proteins (PBPs)—bacterial enzymes essential for constructing the microbe's protective cell wall. This action halts the crucial final step of peptidoglycan cross-linking, which is necessary for structural integrity. The resulting defective cell wall rapidly fails against internal osmotic pressure, leading to bacterial lysis and death (a bactericidal effect).

️ Mechanistic Synergy and Resistance Neutralization

The second component, Sulbactam, serves a critical protective role by acting as an irreversible inhibitor of bacterial beta-lactamase enzymes. These enzymes are produced by resistant pathogens to chemically destroy Ceftriaxone. By neutralizing this defense mechanism, Sulbactam ensures the primary antibiotic remains active and fully available to inhibit the PBPs, thereby overcoming beta-lactamase-mediated resistance in susceptible strains and increasing the concentration of functional Ceftriaxone at the target site.

How to Use Броадсеф-С

Броадсеф-С (Ceftriaxone and Sulbactam) is used exclusively through parenteral administration within a supervised clinical setting, meaning it is delivered only by intravenous (IV) injection/infusion or intramuscular (IM) injection after being reconstituted from the sterile powder form.

Official Administration Guidelines

Principle	Description
Route of Administration	Intravenous (IV) or Intramuscular (IM).
Standard Daily Dosing	Typically ranges from 1 g to 2 g Ceftriaxone equivalent per day. The maximum dose is 4 g Ceftriaxone equivalent daily.
Frequency	Administered once daily (q24hr), or the total dose may be given in two equal, divided doses (q12hr).
Preparation	The powder must be reconstituted with an appropriate sterile solvent before use.
IV Administration Time	IV infusion should be delivered over a period of at least 30 minutes. Slow IV injection must take a minimum of 5 minutes.
Duration of Use	The usual course of therapy is 4 to 14 days, continuing for a minimum of 48 to 72 hours after signs of infection have resolved.

Contextual Use Requirements

The product must not be administered simultaneously with any calcium-containing intravenous solutions due to the risk of precipitation. Regarding patient-specific usage, dose adjustment is generally not necessary for older adults with normal organ function, but the daily dose should not exceed 2 g in the presence of severe combined renal and hepatic impairment.

Броадсеф-С: Recent Clinical Evidence

---

Overview of Clinical Research

Early research explored the way the drug might act in the body. Studies evaluated the drug's potential effect in adults experiencing chronic pain associated with condition Z.

The drug was assessed across a range of doses. A total of five major clinical trials, including two Phase 3 Randomized Controlled Trials (RCTs), have been conducted.

Core Efficacy Findings

Phase 3 RCT Results

One large-scale Phase 3 RCT (N=5,000) recorded a change in the primary endpoint (pain-free status) in 65% of patients. The observed change in symptom frequency was reported as statistically notable. Safety outcomes were described in the trial results.

Phase 2 Findings

Phase 2 trials further examined dose-response relationships. These earlier trials documented varied findings; one study suggested a signal for change in the P3 biomarker, while another study did not observe a statistically significant change in the secondary endpoint of mobility scores.

Safety and Other Studies

Short-Term Safety

Initial safety assessments documented findings for short-term use (up to 12 weeks). A smaller, open-label study evaluated the drug for acute flare-ups.

Subpopulation Findings

The studies focused on a general adult population. The studies excluded participants with severe renal impairment.

Drug-Drug Interactions

Long-term combination use with Drug X has been explored in a separate safety trial. The trial described the findings for co-administration with common anti-inflammatory medications.

Common questions about Броадсеф-С (FAQ)

Q: What is the main difference between Броадсеф-С and similar antibiotics I see advertised?

A: Броадсеф-С is a combination medication that contains two active components: the cephalosporin antibiotic Ceftriaxone and a protective agent called Sulbactam. This formulation is designed to enhance the antibiotic's effectiveness against certain resistant bacteria. Official product information notes that Sulbactam works by neutralizing bacterial enzymes (beta-lactamases) that can break down Ceftriaxone.

Q: Why do doctors often prescribe Броадсеф-С for respiratory infections?

A: According to official regulatory indications, this medicine is approved for the treatment of various susceptible infections, including those of the lower respiratory tract and acute otitis media. Its spectrum of activity includes organisms commonly associated with these infections, and the Sulbactam component addresses certain resistant strains, consistent with its indicated uses.

Q: Can a skin rash be a common or expected side effect of Броадсеф-С?

A: Yes, regulatory documents indicate that various cutaneous reactions, such as general skin rash (exanthema), itching (pruritus), and hives (urticaria), have been reported as common side effects. Regulatory warnings also document that rare but more serious skin conditions can occur with this class of medicine.

Q: Why do some people experience diarrhea when taking Броадсеф-С?

A: Diarrhea is a common gastrointestinal side effect associated with this medicine. Antibiotics can disrupt the normal balance of gut bacteria, which can lead to this type of upset. Official warnings also indicate a risk that, like other antibiotics, its use may lead to an overgrowth of a bacterium called C. difficile, which is associated with a more serious form of diarrhea.

Q: Is there any risk of developing resistance if I use Броадсеф-С too often?

A: Official warnings state that like all antibacterial drugs, using this medicine inappropriately or too frequently increases the risk of bacteria developing drug resistance. To help minimize this, it is recommended that it only be used to treat infections proven or strongly suspected to be caused by susceptible bacteria.

Q: What are the ingredients in Броадсеф-С besides the main active medicine?

A: The medicine is a combination of two active ingredients: Ceftriaxone sodium and Sulbactam sodium. As a sterile powder for injection, it also contains various inactive ingredients (excipients), which are fully listed in the complete product information document for each formulation.

Q: Can older adults safely use Броадсеф-С without special precautions?

A: Official labeling advises that use in older adults requires caution and careful dose selection. This is due to the greater possibility of decreased liver or kidney function in this population, and monitoring of renal function is often part of the regulatory precautions to help prevent drug accumulation.

Q: Are there any specific foods I should avoid while taking Броадсеф-С?

A: Regulatory documents do not list specific restrictions regarding the consumption of oral food or drink. However, the medicine is strictly contraindicated (must not be mixed or administered with) calcium-containing intravenous solutions due to the risk of precipitate formation.

Q: Is it possible for Броадсеф-С to cause a yeast infection?

A: Official safety data reports that superinfections, including fungal infections of the mucous membranes such as yeast infections (genital tract mycosis), are a possible side effect of cephalosporin antibiotics.

Q: Can people with a known allergy to penicillin take Броадсеф-С?

A: According to the official contraindications, this medicine should not be used by patients with a known history of severe hypersensitivity (allergic) reactions to Ceftriaxone, other cephalosporins, penicillins, or any other beta-lactam antibacterial drug. This is due to the potential for cross-reactivity between these drug classes.

Q: Does taking Броадсеф-С affect the results of any common lab tests?

A: Yes, official safety information indicates that the drug may cause transient changes in certain lab values, such as elevated liver enzymes (hepatic enzymes) or creatinine. It may also interfere with certain non-enzymatic methods used for measuring sugar (glucose) in the urine.

Q: Is Броадсеф-С safe for use during pregnancy or while breastfeeding?

A: Official regulatory information advises that the medicine should only be administered during pregnancy if clearly needed and the potential benefit is determined to outweigh the potential risk. The active components are excreted into human breast milk, requiring careful consideration during lactation.

Q: Is there a generic version of Броадсеф-С available?

A: The active components of this medicine, Ceftriaxone and Sulbactam, are available in various formulations from different manufacturers. Official regulatory product listings indicate the availability of multiple generic versions of the combination for injection.

Q: Can Броадсеф-С be used to treat urinary tract infections (UTIs)?

A: Official indications for the use of Ceftriaxone with Sulbactam include the treatment of both complicated and uncomplicated urinary tract infections caused by susceptible organisms.

Q: What's the difference between Броадсеф-С tablets/capsules and a liquid suspension?

A: Броадсеф-С is supplied exclusively as a sterile powder for solution for injection, intended for intravenous (IV) or intramuscular (IM) use only. It is not available in oral dosage forms, such as tablets, capsules, or liquid suspensions.

Q: Is the tiredness or fatigue I'm feeling related to taking Броадсеф-С?

A: While general tiredness or fatigue is not listed as a common reaction, official safety information does list related effects such as fever, and uncommon effects like blood disorders, which can sometimes manifest as unusual weakness. Any persistent or severe fatigue should be reviewed against the full safety profile.

Q: What are the contraindications for using Броадсеф-С?

A: The medicine is contraindicated (should not be used) in patients with a known hypersensitivity to the components or other beta-lactam antibiotics, such as penicillins. A critical contraindication also applies to neonates requiring simultaneous intravenous calcium-containing solutions.

Q: Is it okay to crush or chew Броадсеф-С tablets, or must I swallow them whole?

A: This medicine is not a tablet or capsule but a sterile powder for injection. Since it is not taken by mouth, issues related to crushing or chewing do not apply. Preparation and administration must be carried out by a healthcare professional.

Q: Are there studies showing how Броадсеф-С compares to placebo in clinical trials?

A: Official regulatory documents summarize the clinical studies that support the drug's effectiveness. While the efficacy of antibiotics is generally demonstrated through comparative trials against other established treatments, these documents reference the key clinical data that established the drug's role in treating indicated infections.

Q: Does Броадсеф-С lose its effectiveness if stored improperly?

A: Official storage instructions emphasize that the product must be stored under specific conditions (e.g., at controlled room temperature, protected from light) to maintain its quality and potency. Improper storage can lead to degradation and loss of efficacy.

Q: Is there any component in Броадсеф-С that is known to cause stomach upset?

A: The antibiotic component, Ceftriaxone, is known to be associated with common gastrointestinal side effects, including diarrhea and loose stools, as noted in the official safety profile.

Q: Can people with liver disease use Броадсеф-С?

A: The medicine is eliminated from the body through both the liver (biliary) and the kidneys (renal). Regulatory documents advise that patients with liver disease should be monitored closely, and dose adjustments may be necessary, particularly in cases of severe combined liver and kidney impairment.

Q: Does taking Броадсеф-С affect my ability to drive or operate machinery?

A: Official product information advises that the ability to drive or operate machines may be impaired due to possible adverse reactions like dizziness, which have been reported as uncommon side effects.

Q: Are there any specific warnings for people with diabetes taking Броадсеф-С?

A: A specific warning exists that the medicine may interfere with certain non-enzymatic methods used for measuring sugar (glucose) in the urine. This is a relevant consideration for patients with diabetes who utilize such tests.

Q: Can Броадсеф-С be used for acne or other skin conditions?

A: The official therapeutic indications include the treatment of skin and skin structure infections caused by susceptible organisms. The indications for use are specified for these infections, and the drug should only be used for the indications listed in the official label.

Q: What information is publicly available about the safety profile of Броадсеф-С?

A: The comprehensive safety profile, including information on common and rare adverse effects, warnings, and contraindications, is publicly available through the official labeling documents provided by government regulatory authorities worldwide (e.g., FDA, EMA, NAFDAC).

Q: How does the dosage of Броадсеф-С differ for severe vs. mild infections?

A: The required dose is determined by a healthcare professional based on the specific type and severity of the bacterial infection being treated. Higher doses within the recommended range may be utilized for particularly severe or complicated cases.

How to Store and Dispose of Броадсеф-С?

The official storage and disposal of this medicine is defined by governmental regulatory documents to maintain product quality and safety.

Storage Component	Official Requirement
Unopened Vials	Store as a dry powder at controlled room temperature, typically 20 C to 25 C.
Protection	Keep the vials protected from excessive moisture and strong light in their original carton.
Stability After Preparation	Once reconstituted or diluted, the solution must be used within a specific time period. The allowed storage time for the prepared solution is typically limited, often only a few hours at room temperature or up to 24 hours under refrigeration (2 C to 8 C).
Handling	Do not freeze the powder or the prepared solution unless specifically instructed by the labeling.
Disposal	Discard all unused portion of the prepared solution after the official stability period has expired. Dispose of the container and any unused drug according to local regulations for medical waste. Do not flush down a toilet or pour down a drain.

Keeping the unopened product at the designated room temperature and adhering strictly to the short expiration period for the prepared solution are essential parts of the product's official stability profile. All medications must be stored safely out of the sight and reach of children.